Kestra Advisory Services LLC Has $69.56 Million Position in Eli Lilly and Company $LLY

Key Points

• Kestra Advisory Services LLC increased its holdings in Eli Lilly and Company by 1.6% during the 1st quarter, now owning approximately $69.56 million worth of shares.
• Analysts have varied opinions on Eli Lilly, with upgrades and downgrades leading to an average rating of "Moderate Buy" and a price target of $950.17.
• CEO David A. Ricks recently purchased 1,632 shares at a price of $644.77 per share, raising his ownership stake in the company.

Kestra Advisory Services LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 84,220 shares of the company's stock after buying an additional 1,300 shares during the period. Kestra Advisory Services LLC's holdings in Eli Lilly and Company were worth $69,558,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. WestEnd Advisors LLC increased its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the period. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the first quarter worth $40,000. Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company during the fourth quarter valued at $43,000. Finally, O Brien Wealth Partners LLC grew its holdings in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after acquiring an additional 12 shares during the period. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Guggenheim decreased their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Finally, Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $950.17.

Insider Activity at Eli Lilly and Company

In other news, CEO David A. Ricks bought 1,632 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Up 0.5%

Shares of NYSE LLY opened at $708.8230 on Friday. The business's fifty day moving average price is $756.85 and its 200-day moving average price is $791.70. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.53. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a market capitalization of $670.87 billion, a PE ratio of 46.33, a P/E/G ratio of 0.98 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company earned $3.92 earnings per share. The business's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.